Impact of sex, age at onset, and anti-cN1A antibodies on sporadic inclusion body myositis

被引:0
|
作者
Yamashita, Satoshi [1 ,2 ]
Tawara, Nozomu [1 ]
Sugie, Kazuma [3 ]
Suzuki, Naoki [4 ]
Nishino, Ichizo [5 ]
Aoki, Masashi [4 ]
机构
[1] Kumamoto Univ, Grad Sch Med Sci, Dept Neurol, Kumamoto, Japan
[2] Int Univ Hlth & Welf, Narita Hosp, Dept Neurol, 852 Hatakeda, Narita, Chiba 2868520, Japan
[3] Nara Med Univ, Sch Med, Dept Neurol, Kashihara, Japan
[4] Tohoku Univ, Grad Sch Med, Dept Neurol, Sendai, Japan
[5] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neuromuscular Res, Kodaira, Japan
基金
日本学术振兴会;
关键词
Sporadic inclusion body myositis (IBM); Ages at onset; Disease duration; Gender; Cytoplasmic 5 '-nucleotidase 1 a autoantibody; CYTOSOLIC 5'-NUCLEOTIDASE 1A; ALZHEIMERS-DISEASE; CLINICAL-FEATURES; AUTOANTIBODIES;
D O I
10.1016/j.jns.2024.123164
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Inclusion body myositis (IBM) is a progressive myopathy occurring in patients over 45 years of age, with heterogeneous and variable clinical features. This study aimed to determine the influence of autoantibodies, gender, and age of onset on the clinical features of IBM. Methods: Medical records and muscle histology findings of 570 participants with suspected IBM were reviewed. Various characteristics of patients who met the 2011 ENMC IBM diagnostic criteria were compared based on the presence of anti-cytosolic 5 '-nucleotidase 1 A (cN1A) autoantibodies, gender, age of onset, and disease duration. Results: Of the 353 patients who met the criteria, 41.6% were female. The mean age at onset was 64.6 +/- 9.3 years, and the mean duration from onset to diagnosis was 5.7 +/- 4.7 years. 196 of the 353 patients (55.5%) were positive for anti-cN1A autoantibodies and 157 were negative. Logistic regression showed that patients with anticN1A autoantibodies had a higher frequency of finger flexion weakness. Multiple regression showed that patients with later age of onset had shorter disease duration, lower BMI, and lower serum CK levels. Male patients had a higher frequency of onset with finger weakness and female patients had a lower BMI. Conclusion: Autoantibodies, gender, age of onset, and disease duration may influence the clinical presentation of IBM, highlighting the need for a precision medicine approach that considers these factors along with the underlying mechanisms of the disease.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] PREVALENCE OF ANTI-CN1A ANTIBODIES AND ITS CLINICAL SIGNIFICANCE - A RETROSPECTIVE MONOCENTRIC STUDY
    Silva, S. P.
    Fortes, C.
    Eugenio, G.
    Barcelos, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 2002 - 2003
  • [32] Treatment of Sporadic Inclusion Body Myositis with an Anti-Activin Receptor IIB Antibody
    Amato, Anthony A.
    Sivakumar, Kumaraswamy
    Goyal, Namita
    David, William
    Barohn, Richard J.
    Salajegheh, Mohammad
    Laurent, Didier
    Praestgaard, Jens
    Trifilieff, Estelle
    Trendelenburg, Anne-Ulrike
    Glass, David J.
    Roubenoff, Ronenn
    Tseng, Brian S.
    Greenberg, Steven A.
    ANNALS OF NEUROLOGY, 2013, 74 : S93 - S94
  • [33] Upregulation of STAT-1 and cytokine activity in the muscles of patients with sporadic inclusion body myositis but not in hereditary inclusion-body myositis
    Illa, I
    Dalakas, MC
    NEUROLOGY, 1996, 46 (02) : 73004 - 73004
  • [34] Clinicopathological features of sporadic inclusion body myositis with anti-cytosolic 5′-nucleotidase 1A autoantibodies
    Yamashita, S.
    Tawara, N.
    Ikeda, T.
    Hara, K.
    Zhang, Z.
    Zhang, X.
    Doki, T.
    Ando, Y.
    NEUROMUSCULAR DISORDERS, 2019, 29 : S41 - S41
  • [35] Cytosolic 5′-nucleotidase 1A autoimmunity in sporadic inclusion body myositis
    Larman, H. Benjamin
    Salajegheh, Mohammad
    Nazareno, Remedios
    Lam, Theresa
    Sauld, John
    Steen, Hanno
    Won Kong, Sek
    Pinkus, Jack L.
    Amato, Anthony A.
    Elledge, Stephen J.
    Greenberg, Steven A.
    ANNALS OF NEUROLOGY, 2013, 73 (03) : 408 - 418
  • [36] Cytosolic 5′-Nucleotidase 1A Autoimmunity in Sporadic Inclusion Body Myositis
    Larman, H. Benjamin
    Salajegheh, Mohammad
    Nazareno, Remedios
    Lam, Theresa
    Sauld, John
    Steen, Hanno
    Kong, Sek Won
    Pinkus, Jack L.
    Amato, Anthony A.
    Elledge, Stephen J.
    Greenberg, Steven A.
    ANNALS OF NEUROLOGY, 2013, 74 : S94 - S94
  • [37] ANTIBODIES AGAINST CYTOSOLIC 5′-NUCLEOTIDASE 1A IN SPORADIC INCLUSION BODY MYOSITIS: ASSOCIATION WITH CLINICAL AND MRI FEATURES
    Dejthevaporn, R.
    Shah, S.
    Wastling, S.
    Thornton, J.
    Yousry, T.
    Morrow, J. M.
    Machado, P. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1108 - 1108
  • [38] ANTI- C N1A ANTIBODIES IN SOUTH AUSTRALIAN PATIENTS WITH INCLUSION BODY MYOSITIS
    Limaye, Vidya S.
    Lester, Sue
    Blumbergs, Peter
    Greenberg, Steven A.
    MUSCLE & NERVE, 2016, 53 (04) : 654 - 655
  • [39] Apolipoprotein E and alpha-1-antichymotrypsin polymorphisms in sporadic inclusion body myositis
    Gossrau, G
    Gestrich, B
    Koch, R
    Wunderlich, C
    Schröder, JM
    Schroeder, S
    Reichmann, H
    Lampe, JB
    EUROPEAN NEUROLOGY, 2004, 51 (04) : 215 - 220
  • [40] The role of p62/SQSTM1 in sporadic inclusion body myositis
    Nakano, Satoshi
    Oki, Mitsuaki
    Kusaka, Hirofumi
    NEUROMUSCULAR DISORDERS, 2017, 27 (04) : 363 - 369